HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
The PERT Consortium shared a proud post on X:
”We’re excited to share enrollment for HI-PEITHO is now complete! With 544 patients enrolled across 72 sites in the United States in Europe, this landmark trial compares EKOS (Ultrasound Assisted Thrombolysis) with Anticoagulation vs Anticoagulation Alone in the treatment of intermediate-high risk PE patients. The study was a collaboration between The PERT Consortium, University Medical Center Mainz, and Boston Scientific. We extend our congratulations to all investigators and enrollment sites involved in this one-of-a-kind trial that will inform strategies for PE treatment around the world.”
Learn more abouth the HI-PEITHO here.
Enrollment for the HIPEITHO trial has successfully concluded, with 544 patients enrolled across 72 clinical sites in the United States and Europe.
In HIPEITHO Trial, the pivotal, multicenter study compares ultrasound-assisted catheter-directed thrombolysis using the EKOS system plus anticoagulation versus anticoagulation alone in patients with intermediate-high risk pulmonary embolism (PE).
A collaboration between The PERT Consortium, University Medical Center Mainz, and Boston Scientific, HIPEITHO trial represents a major step forward in evaluating treatment strategies for PE.
The results are expected to significantly inform clinical decision-making and global PE management.
Congratulations to all investigators and sites for their contribution to this groundbreaking trial!
Find the latest scientific advancements in thrombosis management featured in Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week